Media headlines about Allergan (NYSE:AGN) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Allergan earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave media coverage about the company an impact score of 44.6708187881544 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news articles that may have impacted Accern’s rankings:
Several research firms have recently issued reports on AGN. Citigroup reduced their target price on shares of Allergan to $215.00 and set a “buy” rating for the company in a report on Tuesday, January 9th. Vetr cut shares of Allergan from a “buy” rating to a “hold” rating and set a $180.97 target price for the company. in a report on Wednesday. ValuEngine downgraded shares of Allergan from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Royal Bank of Canada set a $218.00 price target on shares of Allergan and gave the company a “buy” rating in a research report on Thursday, January 4th. Finally, Mizuho reiterated a “buy” rating and issued a $267.00 target price on shares of Allergan in a research report on Monday, September 25th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company. Allergan currently has an average rating of “Hold” and an average price target of $226.95.
Shares of Allergan (NYSE AGN) opened at $176.05 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.40. The stock has a market cap of $58,551.24, a price-to-earnings ratio of -7.82, a price-to-earnings-growth ratio of 1.26 and a beta of 1.11. Allergan has a 12-month low of $160.07 and a 12-month high of $256.80.
Allergan (NYSE:AGN) last released its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 EPS for the quarter, topping analysts’ consensus estimates of $4.06 by $0.09. The company had revenue of $4.03 billion during the quarter, compared to the consensus estimate of $4.04 billion. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period last year, the firm earned $3.32 EPS. sell-side analysts predict that Allergan will post 16.27 earnings per share for the current fiscal year.
Allergan declared that its Board of Directors has initiated a stock repurchase plan on Monday, September 25th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to purchase up to 2.8% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s leadership believes its stock is undervalued.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 15th. Stockholders of record on Friday, November 17th were issued a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.59%. The ex-dividend date of this dividend was Thursday, November 16th. Allergan’s payout ratio is -12.44%.
In other Allergan news, insider William Meury sold 11,807 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $173.89, for a total value of $2,053,119.23. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Christopher J. Coughlin bought 10,000 shares of the company’s stock in a transaction on Tuesday, December 5th. The stock was bought at an average cost of $163.30 per share, with a total value of $1,633,000.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 17,630 shares of company stock valued at $2,890,057 over the last three months. 0.36% of the stock is currently owned by insiders.
WARNING: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/14/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-allergan-agn-stock-price.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.